Cash, cash equivalents, short- and long-term investments, and interest receivable were $567.4 million as of March 31, 2025. Cullinan continues to expect its cash resources to provide runway into 2028 based on its current operating plan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management’s Strategic Expansion and Financial Stability Bolster Buy Rating for CLN-978 Development
- Cullinan to initiate study of CLN-978 in patients with Sjogren’s disease
- Cullinan Therapeutics to presents REZILIENT1 trial results at ASCO 2025
- Cullinan Management’s Strategic Advancements and Promising Clinical Developments Drive Buy Rating
- Promising Potential of Cullinan Management’s CLN-978 in Rheumatoid Arthritis Treatment Justifies Buy Rating